Drug Approval | August 19, 2024
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
Brimonidine Tartrate Ophthalmic Solution, 0.025% (OTC) is indicated to relieve redness of the eye due to minor eye irritations.
Becomes the first rehab & recovery center in east India to earn NABH accreditation
The clinical trial will be conducted at 19 sites with 10,335 participants across India
Majority of organizations are looking to increase investments in public and hybrid cloud
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
He recently served as Senior Vice President of the API business at Shilpa Pharma Life Sciences for over 3 years
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
Subscribe To Our Newsletter & Stay Updated
